Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $440.68, moving -0.72% from the previous trading session. This change lagged the S&P 500's daily gain of 0.92%. Meanwhile, the Dow ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...

The healthcare sector has struggled to deliver worthwhile returns for investors since 2021, weighed down by several headwinds ...

Vertex Pharmaceuticals Inc. closed 19.80% below its 52-week high of $519.88, which the company reached on November 8th.

Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.

BOSTON - Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (NASDAQ:VRTX) is set to present pivotal Phase 3 data on suzetrigine, an investigational non-opioid pain signal... ByInvesting.com • Oct ...

A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove safe and effective for chronic pain.

EY—the professional services firm originally known as Ernst & Young—reports the dollar value of biopharma M&A deals nosedived 51% during 2024, to 92 from 186 the previous year.

Applicants to the Ph.D. program Concentrations in Medicinal Chemistry, Pharmaceutics and Pharmacology must have, or nearly have, at least a Bachelor’s degree in pharmacy, biology, biochemistry, ...

Vertex Pharmaceuticals' suzetrigine showed lackluster Phase II results, but I still see potential in the non-addictive pain management market given the opioid crisis. Vertex's dominance in the ...

Houston-based Vertex Energy Inc. (OTCPK: VTNRQ) has released its restructuring plan after filing for bankruptcy protection with a move that will cancel and restructure all of its current stock.

NEW YORK, NY / ACCESS Newswire / January 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...